Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of TAR-210 versus intravesical chemotherapy in FGFR-altered high-risk non-muscle-invasive bladder cancer after prior BCG
MOH_2025-08-10_014227Phase 3
- Sponsor
- J-C Health Care Ltd., an Israeli corporation, thro
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of erdafitinib, mitomycin c and gemcitabine in bladder cancer (2 arms), sponsored by J-C Health Care Ltd., an Israeli corporation, thro. Primary endpoint: Time living without recurrence or worsening of disease.
02
Drugs
erdafitinibmitomycin cgemcitabine
03
Conditions
bladder cancer
Beyond the preview
Go deeper on MOH_2025-08-10_014227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-08-10_014227.